"Designing Growth Strategies is in our DNA"
1. Introduction
1.1. Report Overview
2. Congenital Heart Disease- Overview
3. Executive Summary
4. Congenital Heart Disease: Pipeline Assessment
4.1. By Stage of Development
4.2. By Route of Administration
4.3. By Drug Class
4.4. By Molecule Type
4.5. By Therapy Area / Indication
4.6. By Drug Target
4.7. By Sponsor
5. Congenital Heart Disease: Company & Drug Profiles
5.1. Clinical Stage
5.1.1. Macitentan – Actelion Pharmaceuticals Ltd.
5.1.1.1. Company Overview
5.1.1.2. Product Description
5.1.1.3. R&D Status & Development Activities
5.1.1.4. Mechanism of Action
5.1.1.5. Molecule Type
5.1.1.6. Stage of Development
5.1.1.7. Indications
5.1.1.8. Route of Administration
5.1.1.9. Funding
5.1.2. Apixaban – Bristol-Myers Squibb Company
5.1.2.1. Company Overview
5.1.2.2. Product Description
5.1.2.3. R&D Status & Development Activities
5.1.2.4. Mechanism of Action
5.1.2.5. Molecule Type
5.1.2.6. Stage of Development
5.1.2.7. Indications
5.1.2.8. Route of Administration
5.1.2.9. Funding
5.1.3. Others
5.2. Preclinical
5.2.1. Company Overview
5.2.2. Product Description
5.2.3. R&D Status & Development Activities
5.2.4. Mechanism of Action
5.2.5. Molecule Type
5.2.6. Indications
5.2.7. Route of Administration
5.2.8. Funding
6. Congenital Heart Disease: An Overview on Dormant & Discontinued Pipeline Candidates
6.1. Overview
6.2. Product Description
6.3. Reason for Discontinuation
7. Congenital Heart Disease: Additional Key Insights
7.1. Epidemiology Overview: Congenital Heart Disease
7.2. Current Market Scenario: Congenital Heart Disease Therapeutics
8. Congenital Heart Disease: News, Press Releases and Conference Details
Note:
1) This Table of Content is tentative and subject to change as the research progresses.
2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.